lobbying_activities: 3439397
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3439397 | a4aa4c2c-6718-4396-b0a6-1ca35164cfe9 | Q3 | APOTEX CORP. | 310973 | APOTEX CORP. | 2025 | third_quarter | TAR | Executive Order 14231 and 14325, Amendment to Duties To Address the Flow of Illicit Drugs Across our Northern Border, provisions relating to the imposition of tariffs on products from Canada and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreements from such tariffs; Executive Order 14257, Regulating Imports With A Reciprocal Tariff To Rectify Practices That Contribute To Large And Persistent Annual United States Goods Trade Deficits, provisions relating to the exemption of pharmaceuticals from reciprocal tariffs; Executive Order 14326, Further Modifying the Reciprocal Tarriff Rate, provisions relating to a zero percent tariff rate for non-patented articles for use in pharmaceutical applications; Federal policy relating to the United States-European Union Framework on an Agreement on Reciprocal, Fair, and Balanced Trade and the exemption of generic pharmaceuticals and their ingredients and precursor materials from tariffs; and Federal policy relating to the Department of Commerce's Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [Docket No. 250414-006] and the exemption of pharmaceuticals compliant with the United States-Mexico-Canada trade agreement from any tariffs implemented following the completion of the Section 232 investigation. | HOUSE OF REPRESENTATIVES,SENATE | 310000 | 0 | 0 | 2025-10-17T09:56:54-04:00 |